AC Immune Secures CHF 10M Upfront Payment in Amended Lilly Collaboration for Tau Inhibitors
ACIU sits 95% above its 52-week low of $1.43.
Summary
AC Immune SA announced an amendment to its collaboration agreement with Eli Lilly, securing a CHF 10 million upfront payment and additional milestones for the development of Tau aggregation inhibitors, with IND-enabling studies commencing soon.
Key Events · M&A and Partnerships · ACIU
-
Upfront Payment Secured
AC Immune received a CHF 10 million upfront payment from Eli Lilly and Company as part of an amended license and collaboration agreement.
-
Amended Collaboration Agreement
The existing agreement with Eli Lilly for the research and development of Tau aggregation inhibitor small molecules for neurodegenerative diseases was amended, continuing the collaboration.
-
Future Milestones & Royalties
AC Immune remains eligible for over CHF 1.7 billion in potential development, regulatory, and commercial milestones, in addition to tiered low double-digit royalty payments.
-
Product Development Progress
Investigational New Drug (IND)-enabling studies for the Tau Morphomer candidates are expected to commence in the first half of 2026.
Analysis · ACIU · Life Sciences
This filing announces a significant amendment to AC Immune's collaboration agreement with Eli Lilly, securing a CHF 10 million upfront payment. This non-dilutive cash infusion represents approximately 4% of AC Immune's current market capitalization, providing substantial financial runway. The continuation and progression of this partnership with a major pharmaceutical company like Eli Lilly, coupled with the imminent start of IND-enabling studies for Tau aggregation inhibitors, signals positive momentum in AC Immune's product development pipeline for neurodegenerative diseases. Investors should view this as a strong validation of AC Immune's Morphomer technology and a de-risking event for its lead candidates.
At the time of this filing, ACIU was trading at $2.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $274.8M. The 52-week trading range was $1.43 to $4.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.